Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Discovery of a small molecule having both potent anti-fibrotic and anti-inflammatory capabilities

View ORCID ProfileHan-Soo Kim, Moon Kee Meang, Saesbyeol Kim, Ji Yong Lee, Baik L. Seong, Ik-Hwan Kim, View ORCID ProfileByung-Soo Youn
doi: https://doi.org/10.1101/770404
Han-Soo Kim
1Department of Biomedical Sciences, Catholic Kwandong University College of Medical Convergence, Gangneung-si, Gangwon-do 25601, Republic of Korea
2Basic Research Division, Biomedical Institute of Mycological Resource, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do 25601, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Han-Soo Kim
Moon Kee Meang
3Osteoneurogen, Inc., Seoul, 08501, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saesbyeol Kim
3Osteoneurogen, Inc., Seoul, 08501, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ji Yong Lee
4Research Institute of Hyperbaric Medicine and Science, Yonsei University Wonju College of Medicine, Wonju-si, Gangwon-do 26426, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baik L. Seong
5Department of Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ik-Hwan Kim
6Department of Biotechnology, Korea University, Seoul 02841, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Byung-Soo Youn
3Osteoneurogen, Inc., Seoul, 08501, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Byung-Soo Youn
  • For correspondence: byung4jc@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstracts

Background Pulmonary and hepatic fibrosis are intractable and fatal human disorders. In our previous study, we found that eupatilin, a chromone-scaffold (CS) derivative (CSD), has a strong anti-fibrotic effect on in vitro fibrogenesis as well as a murine lung fibrosis model. Through structure-activity relationship studies, ONG41008 was identified as a more potent anti-fibrotic and anti-inflammatory CS-analog.

Methods A set of cell imaging studies, transcriptomic analyses, and in vivo mouse model involving bleomycin-induced lung fibrosis (BLM) or a murine nonalcoholic steatohepatitis (NASH) model were conducted to explore how ONG41008 exhibits both anti-fibrotic and anti-inflammatory capabilities. In vitro anti-inflammatory activity of ONG41008 was also investigated in RAW264.7 cells, a mouse monocytic cell line stimulated with LPS.

Findings ONG41008 dismantled latent transforming growth factor complex (LTC), limiting TGFβ to TGFβ receptor via depolymerization of F-actin. ONG41008 was able to reverse pathogenic myofibroblasts into non-pathogenic cell types confirmed by both cell shape changes and global transcriptomics analyses. Expression of macrophages homing chemokines in mouse hepatic stellate cells (HSCs) was significantly mitigated by ONG41008. Orally administered ONG41008 significantly improved onset of lung fibrosis. Oral administration of ONG41008 significantly diminished nonalcoholic fatly liver disease (NFALD) scores. ONG41008 substantially inhibited the production of proinflammatory cytokines, including TNFα and several important chemokines affecting T cells or macrophages. TNFα was situated at the central nod in the LPS-ONG41008-macrophages interactome. ONG41008 inhibited endocytosis of CD14, a LPS coreceptor

Interpretation ONG41008 could be a potent drug for a broad range of fibrotic diseases or hyper-inflammatory diseases.

Funding an Osteoneurogen intramural fund

Evidence before this study We previously showed that eupatilin containing a chromone-scaffold (CS) exclusively found in the plant kingdom effectively prevented in vitro fibrogenesis as well as in bleomycin-induced lung fibrosis model. Importantly, cell reversion representing pathogenic myofibroblasts (pMFB) to an intermediate cell type occurred in vitro, and restimulation of the intermediate cell type was trans-differentiated by long exposure to TGFβ, strongly suggesting that this kind of flexible cell reversion would exist in vivo and shed into light on regenerative capacity in fibrotic diseases. One notable feature associated with eupatilin was able to inhibit epithelial-mesenchymal transition (EMT), which plays a central role in initiation and perpetuation of tissue scarring.

Added value of this study Furthering these intriguing therapeutic capabilities, a more effective and stable analog of eupatilin, called ONG41008, was generated and subjected to ameliorating fibrogenesis and inhibiting the various disease activities associated with pMFB. We found that ONG41008 was a potent inhibitor of TGFβ biogenesis such that binding of active TGFβ to TGF receptor (TGFR) was limited, resulting in cessation of TGFR signaling and EMT was completely inhibited, leading to lesser fibrogenesis. Interestingly, ONG41008-treated pMFB underwent generation of a hybrid interactome comprising of a major nuclear reprogramming one and a minor residual fibrogenic interactome, suggesting that ONG41008 is a driver of cell reversion as we saw in the previous study of eupatilin. Macrophages have been well appreciated for liver inflammation and innate immunity. It turned out that ONG41008 was able to block macrophages-chemoattracting proteins called chemokines and directly acted on macrophages, resulting in blocking gene expression of various proinflammatory and inflammatory cytokines.

Implications of all the available evidence All data considered, we believe that ONG41008 is a potent anti-fibrotic drug candidate. And its effectiveness seems likely related to inhibition of macrophage activation. Accordingly, ONG41008 could be used for dysfunctional immunometabolism like NASH as well as blocking the macrophages-mediated innate immunity like rheumatoid arthritis.

Competing Interest Statement

H-S Kim, I-K Kim, and B-S Youn retain the shares of Osteoneurogen, M-K Meang retains a stock option, and SB Kim is employed by OsteoNeuroGen. The current contents of the ONG41008 data have been granted as the subject of a Korean patent and a US patent and has been subjected to USPTO.

Footnotes

  • bioRxiv Dear Editor, We would like to revise the existing preprint entitling discovery of a small molecule having both potent anti-fibrotic and anti-inflammatory capabilities to bioRxiv (https://www.biorxiv.org/content/10.1101/770404v3). The major reason is we have enormously fortified the preprint with macrophage functions and detailed transcriptomic analysis with depth and width, associated with our drug candidate called ONG41008. The title is unchanging. We have reliably replicated the existing experiments and the addition of the macrophage regulatory functions associated with ONG41008 is a new and daunting discovery. We believe that you shall find what we meant by reading the revised preprint manuscript. We look forward to hearing from your reply. Sincerely, Byung-Soo Youn, Ph.D. CEO (Founder) #411, 128, Gasan digital 1-ro, Geumcheon-gu, Seoul, 08507 Republic of Korea Tel) 822- 6267-2739 Fax) 822-6267-2740 Web) www.osteoneurogen.com Web) www.osteoneurogen.com

  • https://doi.org/10.1101/770404

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 03, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Discovery of a small molecule having both potent anti-fibrotic and anti-inflammatory capabilities
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Discovery of a small molecule having both potent anti-fibrotic and anti-inflammatory capabilities
Han-Soo Kim, Moon Kee Meang, Saesbyeol Kim, Ji Yong Lee, Baik L. Seong, Ik-Hwan Kim, Byung-Soo Youn
bioRxiv 770404; doi: https://doi.org/10.1101/770404
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Discovery of a small molecule having both potent anti-fibrotic and anti-inflammatory capabilities
Han-Soo Kim, Moon Kee Meang, Saesbyeol Kim, Ji Yong Lee, Baik L. Seong, Ik-Hwan Kim, Byung-Soo Youn
bioRxiv 770404; doi: https://doi.org/10.1101/770404

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Toxicology
  • Cell Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4680)
  • Biochemistry (10353)
  • Bioengineering (7670)
  • Bioinformatics (26325)
  • Biophysics (13521)
  • Cancer Biology (10682)
  • Cell Biology (15430)
  • Clinical Trials (138)
  • Developmental Biology (8496)
  • Ecology (12818)
  • Epidemiology (2067)
  • Evolutionary Biology (16848)
  • Genetics (11393)
  • Genomics (15476)
  • Immunology (10610)
  • Microbiology (25204)
  • Molecular Biology (10220)
  • Neuroscience (54447)
  • Paleontology (401)
  • Pathology (1668)
  • Pharmacology and Toxicology (2897)
  • Physiology (4341)
  • Plant Biology (9243)
  • Scientific Communication and Education (1586)
  • Synthetic Biology (2557)
  • Systems Biology (6778)
  • Zoology (1465)